Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=300 HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
Phase 3 N=8,657 Evaluation of Diagnostic HIV Ag/Ab Combo Assay
Human Immunodeficiency Viruses
Primary: Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection — 37; 14; 0; 6113 Blood Specimens
Phase 3 N=33 Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
HIV
Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 4 N=92 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
N/A N=114 Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial
HIV-1
Primary: Number of Participants Reaching Clinical Long Term Component Endpoints — 3; 5; 18; 23 Participants
Phase 1 N=16 Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
Phase 4 N=225 HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
HIV
Primary: Number of Participants With HIV Viral Load Suppression in Plasma — 2; 1; 84; 8 Participants
N/A N=6,350 Universal HIV Screening and Targeted HCV Screening in Emergency Department
Hepatitis C · Hiv
Primary: Prevalence — 78; 118; 2; 9 Participants
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
N/A N=9,572 HIV Screening in the Emergency Department Setting
HIV Infections
Primary: Percentage of Tested Participants Newly Diagnosed as HIV Infected — 6; 3 percentage of tested that are positive
N/A N=571 Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers
SARS-CoV-2
Primary: Number of Participant Health Care Workers With a Positive Rapid, At-home, Point-of-care (POC) SARS-CoV2 IgG Antibody Test. — 8 Participants
N/A N=282,368 Kaiser Permanente HIV Cohort Study
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
N/A N=3,830 Seroepidemiological Study of Pertussis and Other Infectious Diseases
Pertussis Infection
Primary: IgG — 1.254; 1.258 EU/mL(log transformed)
Phase 2 N=195 Early ART to Limit Infection and Establishment of Reservoir
HIV-1 Infection
Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48
Phase 4 N=108 SSRI Effects on Depression and Immunity in HIV/AIDS
Depression · HIV · AIDS
Primary: Natural Killer Cell Activity, Measured in Lytic Units [Bryant J, Day R, Whiteside TL, and Herbeman RB: Calculation of Lytic Units for the Expression of Cell-mediated…
N/A N=18 Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Acute HIV Infection
Primary: Mean White Blood Cell Count Between Treatment Groups at 2 Months — 5904; 4918 white blood cells per microliter (mcL).
N/A N=114 Analytical Treatment Interruption in HIV Positive Patients
HIV-1 Infection
Primary: Assessment of the Number of Participants With a HIV Plasma Viral Load Below the Lower Limit of Detection 48 Weeks Following Interruption of Antiretroviral Treatment — 0…
Phase 2 N=16 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
HIV-1 Infection
Primary: Number of Participants With Virologic Rebound at 8 Weeks After Interruption of Antiretroviral Therapy — 4; 3 Participants
Phase 4 N=68 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
HIV · Hepatitis C · Cirrhosis
Primary: Number of Participants With Sustained Virologic Response (SVR) — 38; 25 Participants
Phase 3 N=24,111 Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
Healthy Donors · HIV Positive
Primary: PRISM HIV O Plus Test Data for Specificity — 10; 15589 participants
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
N/A N=42 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
HIV Infections
Primary: Combined Endpoint Including HIV RNA and HIV DNA — 0; 0 Participants
N/A N=151 Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
HIV Infection
Primary: Baseline HIV DNA Reservoir: Total HIV DNA — 3.83; 3.67; 3.40 Log10 HIV DNA copies/10^6 CD4 T cells — p=0.048
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…